Xiaojia Wang, MD

Xiaojia Wang, MD, is an oncologist in the Department of Breast Medical Oncology at the Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital and a key researcher at the Institute of Cancer and Basic Medicine (IBMC) at the Chinese Academy of Sciences in Hangzhou, China.

Articles by Xiaojia Wang, MD

Xiaojia Wang, MD, oncologist, Department of Breast Medical Oncology, Cancer Hospital, University of Chinese Academy of Sciences, Zhejiang Cancer Hospital

Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC

ByXiaojia Wang, MD

April 14th 2025

Xiaojia Wang, MD, shares responses achieved with the combination of ivonescimab plus chemotherapy in locally advanced unresectable or metastatic TNBC.

Xiaojia Wang, MD

Articles by Xiaojia Wang, MD

Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma